45岁时前列腺癌筛查中的多参数磁共振成像:PROBASE试验第一轮筛查结果
PROBASE试验第一轮筛查中,45岁男性PSA≥3 ng/ml者接受多参数磁共振(mpMRI)及融合活检,由本地与两名参考放射科医生盲法判读。参考判读在PI-RADS 4阈值下对临床显著前列腺癌的灵敏度79%、阴性预测值91%、准确率85%,均优于本地判读的55%、80%、68%。作者认为45岁筛查人群的前列腺MRI判读困难,准确率高度依赖读片者经验,双读可能可取,但将MRI纳入45岁男性前列腺癌筛查前仍需更多数据。
要点
- 45岁筛查人群中,mpMRI判读者间一致性中等(k=0.41)。
- PI-RADS 4阈值下,参考判读对临床显著前列腺癌灵敏度79%,本地判读55%。
- 若以PI-RADS≥4为活检阈值,mpMRI可减少68%阴性活检,避免71%无显著前列腺癌检出。
核心结论
- 在45岁筛查人群中前列腺MRI判读困难,对临床显著前列腺癌的准确率高度依赖读片者经验,双读可能可取。
- 将MRI纳入45岁男性前列腺癌筛查前仍需更多数据。
研究设计与样本
- PROBASE试验(ISRCTN37591328)第一轮筛查中,随机接受立即PSA检测且确认PSA≥3 ng/ml的男性接受mpMRI及MRI/经直肠超声融合活检(靶向联合系统穿刺)。
- mpMRI由本地读片者判读,再由两名参考放射科医生(前列腺MRI经验>10000例)盲法判读,比较本地与参考PI-RADS评分。
- 186名参与者中114名接受了mpMRI和融合活检。
主要发现
- 47名(41%)检出前列腺癌,其中33名(29%)为临床显著前列腺癌(国际泌尿病理学会分级分组≥2)。
- 本地与参考PI-RADS评分读片者间一致性中等(k=0.41)。
- PI-RADS 4阈值下,参考判读对临床显著前列腺癌的灵敏度79%、阴性预测值91%、准确率85%,本地判读分别为55%、80%、68%。
- 参考判读在PI-RADS<3阈值下未漏诊任何前列腺癌病例。
- 若以PI-RADS≥4作为活检阈值,mpMRI可减少68%阴性活检,并避免71%无显著前列腺癌病例的检出。
关键数值与推荐
- PI-RADS 4阈值下,参考判读对临床显著前列腺癌灵敏度79%、阴性预测值91%、准确率85%。
- PI-RADS 4阈值下,本地判读对临床显著前列腺癌灵敏度55%、阴性预测值80%、准确率68%。
- 本地与参考PI-RADS评分读片者间一致性k=0.41。
- 以PI-RADS≥4为活检阈值时,mpMRI减少68%阴性活检、避免71%无显著前列腺癌检出。
临床怎么用
- 作者认为45岁筛查人群中前列腺MRI判读困难,准确率高度依赖读片者经验,双读可能可取。
- 作者指出将MRI纳入45岁男性前列腺癌筛查前仍需更多数据。
局限性
- 作者指出45岁筛查人群前列腺MRI判读困难,准确率高度依赖读片者经验。
- 作者指出将MRI纳入45岁男性前列腺癌筛查前仍需更多数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic resonance imaging (MRI) has been suggested as a tool for guiding biopsy recommendations in prostate cancer (PC) screening. OBJECTIVE: To determine the performance of multiparametric MRI (mpMRI) in young men at age 45 yr who participated in a PC screening trial (PROBASE) on the basis of baseline prostate-specific antigen (PSA). DESIGN, SETTING, AND PARTICIPANTS: Participants with confirmed PSA ≥3 ng/ml were offered mpMRI followed by MRI/transrectal ultrasound fusion biopsy (FBx) with targeted and systematic cores. mpMRI scans from the first screening round for men randomised to an immediate PSA test in PROBASE were evaluated by local readers and then by two reference radiologists (experience >10 000 prostate MRI examinations) blinded to the histopathology. The PROBASE trial is registered as ISRCTN37591328 OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The local and reference Prostate Imaging-Data and Reporting System (PI-RADS) scores were compared, and the sensitivity, negative predictive value (NPV), and accuracy were calculated for both readings for different cutoffs (PI-RADS 3 vs 4). RESULTS AND LIMITATIONS: Of 186 participants, 114 underwent mpMRI and FBx. PC was detected in 47 (41%), of whom 33 (29%) had clinically significant PC (csPC; International Society of Urological Pathology grade group ≥2). Interobserver reliability between local and reference PI-RADS scores was moderate (k = 0.41). At a cutoff of PI-RADS 4, reference reading showed better performance for csPC detection (sensitivity 79%, NPV 91%, accuracy of 85%) than local reading (sensitivity 55%, NPV 80%, accuracy 68%). Reference reading did not miss any PC cases for a cutoff of PI-RADS <3. If PI-RADS ≥4 were to be used as a biopsy cutoff, mpMRI would reduce negative biopsies by 68% and avoid detection of nonsignificant PC in 71% of cases. CONCLUSIONS: Prostate MRI in a young screening population is difficult to read. The MRI accuracy of for csPC detection is highly dependent on reader experience, and double reading might be advisable. More data are needed before MRI is included in PC screening for men at age 45 yr. PATIENT SUMMARY: Measurement of prostate specific antigen (PSA) is an effective screening test for early detection of prostate cancer (PC) and can reduce PC-specific deaths, but it can also lead to unnecessary biopsies and treatment. Magnetic resonance imaging (MRI) after a positive PSA test has been proposed as a way to reduce the number of biopsies, with biopsy only recommended for men with suspicious MRI findings. Our results indicate that MRI accuracy is moderate for men aged 45 years but can be increased by a second reading of the images by expert radiologists. For broad application of MRI in routine screening, double reading may be advisable.
引用
- Boschheidgen M, Albers P, Schlemmer HP, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol. 2023. PMID: 37863727. doi:10.1016/j.eururo.2023.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。